What Is Actually Known About Getting Off 7-OH

Update, August 25, 2026. This article was reported and checked on August 6, and the dated statements below reflect the record as it stood then. Since publication the DEA has issued a temporary scheduling order placing mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I, effective on publication in the Federal Register on August 26, 2026. Those are the three substances described below as proposed, and several products marketed as legal successors to 7-OH contain them; as of August 26 they are controlled. The 7-OH threshold order discussed below still has not issued, and HHS has reopened its comment period on the threshold until September 10, 2026. See our report on the order.

People who have been taking concentrated 7-hydroxymitragynine products daily are losing access to them right now, and many are looking for information about what comes next. A great deal of what they will find is being written by someone with something to sell.

This is an attempt to set out what the published record actually establishes, what it does not, and where the honest gaps are. Some of the answers are thinner than anyone would like. Where the evidence runs out, this article says so rather than filling the space.

Nothing here is medical advice. Decisions about opioid dependence are clinical decisions, and the case for making them with a clinician rather than alone is the single best-supported point in this entire article.

First, The Legal Situation Is Not What Most Coverage Says

As of August 6, no federal scheduling order for 7-OH has been published. A search of the Federal Register returns three documents, all dated July 6: the DEA's notice of intent proposing to place 7-OH above a specified threshold into Schedule I, a companion notice covering mitragynine pseudoindoxyl, MGM-15 and MGM-16, and an HHS request for information. All three are proposals. The thirty-day statutory minimum elapsed on August 5, which means an order may issue at any time — but it has not issued yet.

The practical situation has moved ahead of the legal one. A number of states — nine by this publication's count — now prohibit kratom outright rather than only its concentrated derivatives, Tennessee since July 1 and Connecticut since March 25 among them. Rhode Island moved the other way on April 1, replacing prohibition with a licensed, potency-capped regulatory scheme. Retailers elsewhere have cleared inventory in anticipation of the federal order, and online sellers have run closeout promotions timed to it. Supply has contracted for reasons that have little to do with whether the rule has technically landed.

That gap matters for anyone reading vendor claims about what is and is not "still legal." It is a moving target, and several products currently marketed as legal successors to 7-OH are named in the companion notice covering the same timeline.

What Withdrawal From These Products Looks Like

Here the distinction between kratom leaf and concentrated 7-OH becomes the whole question, and conflating the two produces badly misleading expectations.

The research literature on withdrawal from traditional leaf describes something relatively mild. A 2023 expert forum convened on the question, and published in Drug and Alcohol Dependence Reports, concluded that "moderate daily kratom use… of unadulterated and unaltered kratom leaf material or powder generally does not lead to a significant discontinuation-associated withdrawal syndrome," and that where withdrawal does occur it is "generally milder than observed with chronic frequent opioid, sedative, or stimulant users and generally more tolerable and self-manageable." Malaysian cohort research by Darshan Singh and colleagues found mild anxiety and depression rather than severe, and reported that cessation "is not associated with prolonged pain and sleep problems, as compared to those reported for opioid analgesics."

Those findings should not be carried over to 7-OH products, and the same expert forum said so, noting that products "in which levels of alkaloids are increased beyond what is typically found in natural products may also differ in their potential for physical dependence, withdrawal and other effects."

The pharmacology explains why, and the National Institute on Drug Abuse states the distinction plainly on its own kratom page, updated in March: "Neither kratom leaves nor mitragynine appear to lead to respiratory depression (trouble breathing) that is characteristic of a life-threatening opioid overdose." It continues: "In laboratory models, 7-OH can cause respiratory depression that is reversed by naloxone. Even though the body converts mitragynine to 7-OH, this occurs slowly enough that it limits mitragynine's effects on breathing."

The underlying research supports that reading. Work published in ACS Central Science in 2019 by Kruegel and colleagues established that 7-OH is an active metabolite of mitragynine and the main driver of its opioid effects. A 2020 comparison by Obeng and colleagues found that mitragynine itself behaves as a mu-opioid receptor antagonist in one standard assay, while 7-OH is a partial agonist — and 2006 work by Matsumoto's group put 7-OH at several times the potency of morphine in animal analgesia models. A 2025 rat study led by Zuarth Gonzalez found the two move in opposite directions on breathing: 7-OH depressed respiration with a potency roughly four and a half times that of morphine, while mitragynine increased respiratory rate.

This is also the arithmetic behind the federal threshold. Analysis published in Pharmaceutical Biology in late 2025 measured 7-OH in natural leaf at between 0.011 and 0.039 percent by weight — below the 0.050 percent line the DEA has proposed, which is why the proposal reaches concentrates without reaching the leaf.

Leaf and concentrate are not two strengths of the same thing. Analytical work published this year found that more than 98 percent of products labelled as containing 7-OH were semisynthetic, with labelled doses ranging across four orders of magnitude and substantial label inaccuracy throughout.

The published case reports on 7-OH withdrawal describe ordinary opioid withdrawal. One 2026 case documented onset within eight hours of the last dose. Another recorded a Clinical Opiate Withdrawal Scale score peaking at 14. A third described a man who had moved from kratom to 7-OH eighteen months earlier and was taking 360 mg a day.

The Timeline, Which Is The Part Worth Holding Onto

Acute withdrawal from short-acting opioids follows a reasonably well-characterised course. A 2019 review by Kosten and Baxter in The American Journal on Addictions describes onset within about twelve hours of the last dose, a peak at roughly 36 to 72 hours, tapering over the following four to seven days, and resolution generally between five and fourteen days.

No study has established a withdrawal timeline specific to 7-OH; only onset has been documented. But the general shape is the reason clinicians describe the acute phase as something that ends. The worst of it arrives early and does not stay.

What Has Actually Been Studied — And The Large Hole In The Middle

The honest summary is that the specific strategy most people are attempting has never been tested.

Searches of PubMed for kratom or mitragynine combined with tapering or gradual dose reduction return no study of tapering kratom. ClinicalTrials.gov lists thirteen kratom trials and none on cessation or tapering, and zero trials of any kind on 7-OH cessation. No study reports kratom cessation success rates. No study compares gradual reduction against abrupt stopping. No study at all examines moving from 7-OH back to plain leaf. A 2024 review noted that there are no human laboratory studies of concentrated kratom extracts of any kind.

The 2023 expert forum listed tapering among its research recommendations — calling for evaluation of "gradual kratom and mitragynine dose tapering" alongside lofexidine and clonidine — which is to say it was named as a question worth studying, not as an answer.

Anyone presenting a step-down schedule as clinically established is going beyond the evidence. That includes vendors selling leaf products, and it includes vendors selling research chemicals.

There is a second gap, and it is arguably the more consequential one. This publication could locate no guidance from the FDA, the DEA or HHS directed at people who have been using these products — no tapering advice, no transition pathway, no referral protocol issued alongside the scheduling proposal. The peer-reviewed literature has begun calling for exactly that: a 2025 review in Pharmaceutical Biology recommends "time-limited grace periods… naloxone co-dispensing, and facilitated referral to medications for opioid use disorder." That recommendation implies the absence it describes. Virginia, for its part, now requires 7-OH product labels to carry the words "THIS MAY CAUSE DEPENDENCE AND OPIOID-LIKE WITHDRAWAL," which is a state government stating the risk without addressing what a dependent person should then do.

The order, when it publishes, takes effect that same day. The Federal Register notice provides for no grace period.

What The Tapering Evidence Does Support

The general opioid literature is more developed, though weaker than its confident reputation suggests.

The CDC's 2022 clinical practice guideline states that "opioid therapy should not be discontinued abruptly," and that clinicians "should not rapidly reduce opioid dosages from higher dosages," naming serious withdrawal, worsening pain, psychological distress, overdose, and suicidal ideation among the harms. The CDC assigned that recommendation its lowest evidence tier.

The strongest quantitative support comes from a 2021 JAMA study by Agnoli and colleagues covering 113,618 patients, which found that each 10 percent increase in the maximum monthly rate of dose reduction was associated with a 9 percent higher rate of overdose and an 18 percent higher rate of mental health crisis. Follow-up work found the elevated risk persisting up to two years. These are observational findings, not trials.

Set against that, a Cochrane review of seven trials comparing different buprenorphine taper rates concluded that "it remains very uncertain what effect the rate of dose taper has on treatment outcome," and a systematic review by Frank and colleagues rated the great majority of studies in this field as poor quality.

The defensible position is narrow but real: abrupt discontinuation is associated with harm, faster reduction appears worse than slower, the physiological rationale is well understood — and the head-to-head trial establishing that gradual tapering reduces withdrawal severity has never been run in any population, let alone this one.

The One Approach With Published Outcomes

For 7-OH specifically, the only management described in the medical literature is medication, and the results are encouraging.

A retrospective case series published in 2026 by Fenske and colleagues followed nine patients through a telehealth clinic between April and October 2025. Eight of nine improved at a median of six weeks, buprenorphine was successfully initiated in nearly all, and no precipitated withdrawal occurred. Separate case reports describe successful treatment with buprenorphine and, in one instance, methadone followed by low-dose buprenorphine.

Nine patients is a small number, and a case series is not a trial. It is nonetheless the only body of published outcomes that exists, and every case in it involved a clinician.

Speaking to WHYY in May, Jeanmarie Perrone of the Penn Center for Addiction Medicine and Policy described long-acting buprenorphine as "extremely effective for opioid use disorder." Corneliu Stanciu of Dartmouth's Geisel School of Medicine put the risk of the products themselves more bluntly in the same reporting, saying of concentrated 7-OH that "it's just like ingesting fentanyl. So you get the respiratory depression and death after that."

One caution belongs alongside this, and it comes from community reports rather than published research: people describe standard buprenorphine doses providing less relief than expected in 7-OH withdrawal, in some cases for several days. Those accounts are anecdotal and unverified. They are worth raising with a prescriber in advance precisely because someone who expects immediate relief, does not get it, and concludes that treatment has failed is at high risk of returning to use.

What People Describe Doing, Labelled As What It Is

Published research on community experience is limited but not absent. A 2024 study in Frontiers in Pharmacology by Rogers and colleagues analysed 370 posts across kratom-related forums and found that quitting, tapering or reducing was the second most frequently coded theme, behind addiction and dependence. Its most relevant finding for this moment: extract products were positively associated with reports of perceived addiction and dependence, and nearly every consumer of extracts who wanted to quit or had quit described indicators of physical dependence.

Within community discussion, the approaches described most often are self-directed gradual reduction, switching from concentrate to plain leaf, stopping abruptly, and seeking medication treatment. Stopping abruptly is widely discouraged by the people who have tried it. The switch to plain leaf is contested, and it is worth noting that the parties on each side of that argument frequently sell one of the two options.

This is anecdote. It reflects what people say worked for them, which is not the same as evidence, and the population posting in recovery forums is not a representative sample.

Several Things Being Suggested Are Worse Than The Problem

Loperamide taken at very high doses circulates as a withdrawal remedy. It carries documented risk of QT prolongation and torsades de pointes, and has killed people.

Ibogaine clinics are advertising to this population, including with success-rate claims. Ibogaine is Schedule I in the United States and carries documented cardiac fatality risk.

SR-17018, sold online as "SR-17," is a synthetic opioid unrelated to kratom that the DEA has moved to schedule on a finding of physical dependence, and which has never been administered to a human in a registered trial. This publication examined it separately.

And the newer compounds being marketed as legal replacements — mitragynine pseudoindoxyl and MGM-15 among them — are named in the DEA's companion notice on the same timeline as 7-OH itself.

Reason For Some Optimism

Two findings deserve more attention than they get.

In a 2022 assessment by Smith and colleagues of 129 current and former kratom consumers, more than a third reported at least one quit attempt, 17.8 percent met criteria for remission, and over half had never met criteria for a use disorder at all. Notably, the disorder in that sample was driven by tolerance and withdrawal rather than by disruption to people's lives — fewer than one in ten reported interference with work or family obligations.

And the acute phase is finite. It is genuinely unpleasant, it arrives fast, it peaks within a few days, and for most people it resolves within about two weeks. That is a hard fortnight, not an indefinite condition.

Poison centre data shows what is at stake in doing this without support: America's Poison Centers reported in July that 7-OH-involved cases rose sharply through the first half of 2026, with more than a third of 7-OH exposures resulting in serious medical outcomes and roughly one in five requiring hospitalisation. Clinicians quoted in regional coverage have warned that an abrupt loss of supply could push dependent people toward the illicit opioid market, where fentanyl contamination is the norm. That is the outcome worth organising everything else around avoiding.

Where To Get Help

The SAMHSA National Helpline is free, confidential, and staffed 24 hours a day, 365 days a year, in English and Spanish: 1-800-662-HELP (4357), TTY 1-800-487-4889, or text your ZIP code to 435748.

findtreatment.gov lists licensed treatment providers by location, including prescribers of buprenorphine and methadone.

The 988 Suicide & Crisis Lifeline can be reached by call, text or chat at 988. For Spanish, press 2 or text AYUDA; veterans press 1.

Poison Control is available at 1-800-222-1222 and through the webPOISONCONTROL online tool, free and confidential.

If someone is unresponsive or breathing slowly or irregularly, that is an emergency. Call 911. Naloxone reverses opioid overdose and is available without a prescription in every state.

A Note On The Sources

Industry funding runs through a meaningful share of the kratom literature, and readers should weigh it. Several authors of the 2023 expert forum are affiliated with a regulatory consulting firm serving the supplement industry, and one declares a paid advisory role with a kratom company. Some widely cited consumer surveys were distributed through kratom trade associations. Other work cited here was produced by NIDA's intramural program, the FDA, and academic groups without industry ties. The Kratom Council is owned by NWB Distribution LP, which sells kratom leaf products and does not sell 7-OH, synthetic derivatives or research chemicals; that interest is disclosed on every page of this site.